Evolus Inc. Insider Trading

EOLS

Last 12 months

Insiders sold $1.84M and bought nothing on the open market.

48% of the selling was scheduled in advance under 10b5-1 plans. See Remarks David Moatazedi sold 950K on Sep 2, 17% of their stake, outside a plan. The last open-market buy by an executive or director was in Aug 2025.

Net open-market

−$1.84M

0 buys · 7 sales

Under a 10b5-1 plan

48%

of the value sold

Insiders who bought / sold

0 / 2

executives and directors

Last open-market buy

Aug 2025

Aug 15, 2025

Get an email when EOLS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 2	David Moatazedi See Remarks	SoldNo plan	105,108	$9.04	950K	17%	Form 4
Mar 20	Rui Avelar See Remarks	Sold10b5-1 plan	3,119	$4.75	15K	0.7%	Form 4
Mar 20	David Moatazedi See Remarks	Sold10b5-1 plan	13,669	$4.75	65K	2.2%	Form 4
Mar 17	David Moatazedi See Remarks	Sold10b5-1 plan	116,720	$4.89	571K	16%	Form 4
Mar 17	Rui Avelar See Remarks	Sold10b5-1 plan	29,996	$4.89	147K	6.5%	Form 4
Dec 22, 2025	David Moatazedi See Remarks	Sold10b5-1 plan	10,539	$7.15	75K	2.9%	Form 4
Dec 22, 2025	Rui Avelar See Remarks	Sold10b5-1 plan	2,261	$7.15	16K	0.6%	Form 4
Aug 22, 2025	Tomoko Yamagishi-Dressler Chief Marketing Officer	Sold10b5-1 plan	5,722	$7.51	43K	6.0%	Form 4
Aug 15, 2025	Brady Stewart Director	Bought	30,000	$6.82	205K	51%	Form 4
Jun 13, 2025 – Jun 16, 2025	David Moatazedi See Remarks	SoldNo plan 2 parts	127,905	$10.03 average	$1.28M	26%	Form 4
Jun 9, 2025	Albert G White III Director	Bought	20,000	$9.45	189K	66%	Form 4
May 13, 2025	Sandra Beaver Chief Financial Officer	Sold10b5-1 plan	6,494	$10.02	65K	3.7%	Form 4
May 12, 2025	Rui Avelar See Remarks	Sold10b5-1 plan	3,385	$9.87	33K	0.9%	Form 4
May 12, 2025	David Moatazedi See Remarks	Sold10b5-1 plan	15,787	$9.87	156K	3.1%	Form 4
Mar 27, 2025	David Moatazedi See Remarks	Sold10b5-1 plan	6,251	$12.40	78K	1.2%	Form 4
Mar 18, 2025	Rui Avelar See Remarks	Sold10b5-1 plan	27,904	$13.26	370K	7.1%	Form 4
Mar 18, 2025	Sandra Beaver Chief Financial Officer	Sold10b5-1 plan	8,996	$13.26	119K	4.9%	Form 4
Mar 18, 2025	Tomoko Yamagishi-Dressler Chief Marketing Officer	Sold10b5-1 plan	4,536	$13.26	60K	4.5%	Form 4
Mar 18, 2025	David Moatazedi See Remarks	Sold10b5-1 plan	103,376	$13.26	$1.37M	17%	Form 4
Mar 12, 2025	Karah Herdman Parschauer Director	SoldNo plan	12,888	$12.99	167K	29%	Form 4
Dec 23, 2024	Rui Avelar See Remarks	Sold10b5-1 plan	2,252	$10.85	24K	0.6%	Form 4
Dec 23, 2024	Sandra Beaver Chief Financial Officer	Sold10b5-1 plan	1,586	$10.85	17K	1.1%	Form 4
Dec 23, 2024	David Moatazedi See Remarks	Sold10b5-1 plan	10,502	$10.85	114K	2.0%	Form 4

Sep 2No plan
David Moatazedi
See Remarks · sold 105,108 at $9.04
950K
17% of stake
Mar 2010b5-1 plan
Rui Avelar
See Remarks · sold 3,119 at $4.75
15K
0.7% of stake
Mar 2010b5-1 plan
David Moatazedi
See Remarks · sold 13,669 at $4.75
65K
2.2% of stake
Mar 1710b5-1 plan
David Moatazedi
See Remarks · sold 116,720 at $4.89
571K
16% of stake
Mar 1710b5-1 plan
Rui Avelar
See Remarks · sold 29,996 at $4.89
147K
6.5% of stake
Dec 22, 202510b5-1 plan
David Moatazedi
See Remarks · sold 10,539 at $7.15
75K
2.9% of stake
Dec 22, 202510b5-1 plan
Rui Avelar
See Remarks · sold 2,261 at $7.15
16K
0.6% of stake
Aug 22, 202510b5-1 plan
Tomoko Yamagishi-Dressler
Chief Marketing Officer · sold 5,722 at $7.51
43K
6.0% of stake
Aug 15, 2025
Brady Stewart
Director · bought 30,000 at $6.82
205K
51% of stake
Jun 13, 2025 – Jun 16, 2025No plan
David Moatazedi
See Remarks · sold 127,905 at avg $10.03
$1.28M
26% of stake
Jun 9, 2025
Albert G White III
Director · bought 20,000 at $9.45
189K
66% of stake
May 13, 202510b5-1 plan
Sandra Beaver
Chief Financial Officer · sold 6,494 at $10.02
65K
3.7% of stake
May 12, 202510b5-1 plan
Rui Avelar
See Remarks · sold 3,385 at $9.87
33K
0.9% of stake
May 12, 202510b5-1 plan
David Moatazedi
See Remarks · sold 15,787 at $9.87
156K
3.1% of stake
Mar 27, 202510b5-1 plan
David Moatazedi
See Remarks · sold 6,251 at $12.40
78K
1.2% of stake
Mar 18, 202510b5-1 plan
Rui Avelar
See Remarks · sold 27,904 at $13.26
370K
7.1% of stake
Mar 18, 202510b5-1 plan
Sandra Beaver
Chief Financial Officer · sold 8,996 at $13.26
119K
4.9% of stake
Mar 18, 202510b5-1 plan
Tomoko Yamagishi-Dressler
Chief Marketing Officer · sold 4,536 at $13.26
60K
4.5% of stake
Mar 18, 202510b5-1 plan
David Moatazedi
See Remarks · sold 103,376 at $13.26
$1.37M
17% of stake
Mar 12, 2025No plan
Karah Herdman Parschauer
Director · sold 12,888 at $12.99
167K
29% of stake
Dec 23, 202410b5-1 plan
Rui Avelar
See Remarks · sold 2,252 at $10.85
24K
0.6% of stake
Dec 23, 202410b5-1 plan
Sandra Beaver
Chief Financial Officer · sold 1,586 at $10.85
17K
1.1% of stake
Dec 23, 202410b5-1 plan
David Moatazedi
See Remarks · sold 10,502 at $10.85
114K
2.0% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch EOLS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with EOLS

CompareIntrinsic value

ARVNArvinas Inc.

$7.42+4.65%40

XERSXeris Biopharma Holdings, Inc.

$10.46+1.06%30

AUPHAurinia Pharmaceuticals Inc.

$17.11+3.32%58

LQDALiquidia Corporation

$47.38+12.27%72

VREOFVireo Growth Inc.

$7.29-2.15%30

RIGLRigel Pharmaceuticals, Inc.

$51.29+4.97%87

LGNDLigand Pharmaceuticals Inc.

$316.13+0.83%36

MNKDMannKind Corporation

$3.93+5.36%30

Held by ETFs

EOLS is in 12 US ETFs. The largest of them, with EOLS's weight in each:

Spot a number that looks wrong? Check it in EOLS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing EOLS

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.